tadalafil has been researched along with Raynaud Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández-Codina, A; Kazem, M; Pope, JE | 1 |
| Allanore, Y; Blaise, S; Caglayan, E; Carpentier, PH; Cracowski, JL; Roustit, M | 1 |
| Kamata, Y; Minota, S | 1 |
| Hsu, VM; Impens, AJ; McCloskey, DA; Phillips, K; Rothman, JA; Schiopu, E; Seibold, JR; Wilson, JE | 1 |
| Agarwal, V; Choudhary, SK; Jha, LK; Kumar, S; Misra, R; Shenoy, PD; Singh, U | 1 |
| Baumhaekel, M; Boehm, M; Scheffler, P | 1 |
| Friedman, EA; Harris, PA; Kurnik, D; Stein, CM; Wood, AJ | 1 |
1 review(s) available for tadalafil and Raynaud Disease
| Article | Year |
|---|---|
Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.
Topics: Carbolines; Humans; Imidazoles; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Raynaud Disease; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2013 |
3 trial(s) available for tadalafil and Raynaud Disease
| Article | Year |
|---|---|
Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
Topics: Adult; Carbolines; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Prospective Studies; Raynaud Disease; Scleroderma, Systemic; Tadalafil; Treatment Outcome | 2009 |
Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
Topics: Adult; Carbolines; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Tadalafil; Treatment Outcome; Vasodilator Agents; Young Adult | 2010 |
The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Carbolines; Cold Temperature; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Double-Blind Method; Female; Humans; Male; Phosphodiesterase Inhibitors; Raynaud Disease; Regional Blood Flow; Skin; Skin Temperature; Tadalafil; Vasoconstriction | 2007 |
3 other study(ies) available for tadalafil and Raynaud Disease
| Article | Year |
|---|---|
Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
Topics: Administration, Cutaneous; Adult; Aged; Female; Fingers; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Raynaud Disease; Scleroderma, Systemic; Skin Cream; Tadalafil; Ulcer | 2020 |
Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon.
Topics: Administration, Oral; Adult; Aged; Carbolines; Female; Fingers; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Prospective Studies; Purines; Raynaud Disease; Regional Blood Flow; Sildenafil Citrate; Skin Temperature; Sulfonamides; Sulfones; Tadalafil; Thermography; Time Factors; Treatment Outcome; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2014 |
Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Brachial Artery; Capillaries; Carbolines; Fingers; Humans; Laser-Doppler Flowmetry; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Raynaud Disease; Regional Blood Flow; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Ultrasonography | 2005 |